Plus Therapeutics Says CNSide Leptomeningeal Metastases FORSEE Trial Met Key Primary And Secondary Endpoints
Author: Benzinga Newsdesk | August 13, 2024 07:32am
The data were presented in a podium presentation at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, 2024 in Denver, Colorado.
The trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target
Posted In: PSTV
